# Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer

> **NCT05965479** · PHASE2 · RECRUITING · sponsor: **University of Southampton** · enrollment: 25 (estimated)

## Conditions studied

- Gastrooesophageal Cancer

## Interventions

- **DRUG:** Trastuzumab deruxtecan

## Key facts

- **NCT ID:** NCT05965479
- **Lead sponsor:** University of Southampton
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-10
- **Primary completion:** 2026-03-31
- **Final completion:** 2028-04-30
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2024-11-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05965479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05965479, "Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05965479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*